Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus recommendation of “Hold” by the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $12.63.
Several analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, August 14th. Morgan Stanley reduced their price objective on shares of Y-mAbs Therapeutics from $7.00 to $5.00 and set an “underweight” rating on the stock in a research note on Monday, August 14th. Bank of America increased their price target on shares of Y-mAbs Therapeutics from $6.00 to $12.00 in a research note on Monday, May 15th. Wedbush raised shares of Y-mAbs Therapeutics from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $5.00 to $13.00 in a research note on Wednesday, May 10th. Finally, Canaccord Genuity Group increased their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, July 25th.
View Our Latest Analysis on Y-mAbs Therapeutics
Y-mAbs Therapeutics Trading Down 2.0 %
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its position in shares of Y-mAbs Therapeutics by 924.1% in the 1st quarter. Tower Research Capital LLC TRC now owns 5,899 shares of the company’s stock worth $30,000 after buying an additional 5,323 shares during the last quarter. Denali Advisors LLC acquired a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $42,000. Russell Investments Group Ltd. boosted its holdings in shares of Y-mAbs Therapeutics by 1,347.5% in the 1st quarter. Russell Investments Group Ltd. now owns 11,812 shares of the company’s stock valued at $59,000 after buying an additional 10,996 shares during the period. Avestar Capital LLC acquired a new position in shares of Y-mAbs Therapeutics in the 2nd quarter valued at about $68,000. Finally, Graham Capital Management L.P. acquired a new position in shares of Y-mAbs Therapeutics in the 2nd quarter valued at about $68,000. 45.45% of the stock is owned by institutional investors and hedge funds.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Read More
- Five stocks we like better than Y-mAbs Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Reasons High-Yield Bloomin’ Brands is About to Blossom
- How to Invest in Growth Stocks
- 5 Computer Vision Stocks with a Clear Path to Growth
- What Are Dividend Achievers? An Introduction
- 3 Reasons Workday Stock Is Setting Up For A New Rally
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
